US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...
FDA approves first self-administered flu vaccine spray
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...
Nasal Flu Vaccine Is Approved for At-Home Use
The F.D.A. authorized AstraZeneca’s treatment to be given outside a health care setting, although it will still need a ...
US FDA approves AstraZeneca's flu vaccine for self-administration
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
WAPT23h
FDA approves first flu vaccine that can be self-administered at home
FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
oncnursingnews2h
Early Switch to Atezolizumab After Vemurafenib/Cobimetinib Run-in Shows Improved Survival Trend in Melanoma
Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...
devdiscourse3h
Regulatory Milestones and Health Advances: Key Developments in the Pharmaceutical Sector
Recent health news highlights key regulatory approvals and legal actions. The EU backs Novo Nordisk's Wegovy for an ...
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
AstraZeneca: Poised for Growth with Promising Innovation Pipeline and Attractive Valuation
In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on AstraZeneca (AZN – Research Report), with a ...